When was Pepscope founded?

Pepscope was founded in 2012 and raised its 1st funding round 8 years after it was founded.

Where is Pepscope located?

Pepscope is headquartered in The Hague, Netherlands.

How many employees does Pepscope have?

As of Apr 30, 2026, the latest employee count at Pepscope is 3.

Is Pepscope a funded company?

Pepscope is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Dec 14, 2020.

When was the latest funding round of Pepscope?

Pepscope's latest funding was a $***** Series A round on Dec 14, 2020, with participation from 2 investors. Its primary sector is Life Sciences Platforms and Tools. Globally, the Life Sciences Platforms and Tools sector has seen $1.16B in funding in 2026 to date.

Where does Pepscope rank among its competitors?

Pepscope ranks 84th amongst 175 active competitors, of which 31 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Arzeda, which secured $4.51M in Aug, 2025.

Who are the top competitors of Pepscope?

Pepscope's top competitors include Nautilus Biotechnology, Somalogic and Biognosys. Among them, Arzeda secured the most recent funding round in August, 2025.

Pepscope - 2026 Company Profile, Team, Funding & Competitors

Company Details

Pepscope provides services for proteomics using microarray and mass spectrometry. The company develops protein-kinase profiling assays and diagnostics and provides advanced proteomics services with a focus on protein activity profiling, including protein kinases to clients from academia and industry.

Key Metrics

Founded Year

2012

Location

The Hague, Netherlands

Stage

Deadpooled

Total Funding

$5.21M in 1 round

Latest Funding Round

Series A, Dec 14, 2020, $*****

Investors

KIKK Capital & 1 more

Ranked

84^th among 175 active competitors

Employee Count

3 as on Apr 30, 2026

Similar Companies

Nautilus Biotechnology & 235 more

View Pepscope's full profile

Pepscope has raised a total funding of $5.21M over 1 round. Its latest funding round was a Series A round on Dec 14, 2020 for $*****. 2 investors participated in its latest round. Pepscope has 2 institutional investors.

Here is the list of recent funding rounds of Pepscope:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 14, 2020	8187886	Series A	8454099	9740922	5668022	5223534

Access funding benchmarks and valuations. Sign up today!

View details of Pepscope's funding rounds and investors

The founders of Pepscope is Jos Joore.

Here are the details of Pepscope's key team members:

Jos Joore: Co-Founder & CEO of Pepscope.

View details of Pepscope's Founder profiles and Board Members

Pepscope's employee count trend

Pepscope has 3 employees as of Apr 26. Here is Pepscope's employee count trend over the years:

Uncover Pepscope's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pepscope include Nautilus Biotechnology, Somalogic and Biognosys. Here is the list of Top 10 competitors of Pepscope, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nautilus Biotechnology 2016, Seattle (United States), Public	Developer of proteomics platform for drug development	$453M	Vulcan, Bain Capital Life Sciences & 8 others	65/100
2nd	Somalogic 1999, Boulder (United States), Acquired	Developer of protein-based assays for life science research	$664M	ProQuest Investments, ICarbonX & 27 others	64/100
3rd	Biognosys 2008, Schlieren (Switzerland), Acquired	Provider of proteomics service	$9.13M	Zurcher Kantonalbank, Syngenta Group & 6 others	63/100
4th	Arzeda 2008, Seattle (United States), Series B	Developer of enzyme design technology to bridge the gap by creating synthetic enzymes	$95.2M	OS Fund, Conti Ventures & 22 others	58/100
5th	Amunix 2006, Mountain View (United States), Acquired	Developer of peptide-based therapeutics	$201M	Omega Funds, Viking Global Investors & 18 others	57/100
6th	A-Alpha Bio 2017, Seattle (United States), Series A	Developer of cell-based tool for the measurements of protein interactions	$45.2M	Xontogeny, OS Fund & 15 others	56/100
7th	Dynamic Biosensors 2011, Planegg (Germany), Acquired	Provides solutions for label-free molecular interaction and biophysical analysis	$5.83M	Rurode, EXTOREL & 19 others	56/100
8th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
9th	ProteinSimple 2004, San Jose (United States), Acquired	Provider tools to help researchers with protein analysis	$94.3M	Lansing Brown Investments, Royal Bank of Canada ... & 10 others	54/100
10th	Cevec Pharmaceuticals 2001, Cologne (Germany), Acquired	Provider of glyco-optimised human cell lines and gene therapy vectors using proprietary cell expression system	$28.4M	Peppermint VenturePartners, NRW.Bank & 28 others	52/100
84th	Pepscope 2012, The Hague (Netherlands), Deadpooled	Provider of services for proteomics using microarray and mass spectrometry	$5.21M	Oost NL, KIKK Capital	25/100